In adult patients with advanced hepatocellular carcinoma who have progressed on sorafenib, what is the recommended dosing regimen, dose‑adjustment strategy for toxicities, contraindications (e.g., Child‑Pugh C), and required monitoring for regorafenib?

Regorafenib for Hepatocellular Carcinoma

Regorafenib 160 mg orally once daily for 3 weeks on/1 week off is recommended for patients with advanced HCC who progressed on sorafenib (≥400 mg/day for ≥20 of the last 28 days), have Child-Pugh A liver function, and ECOG performance status 0-1. 1, 2

Patient Selection Criteria

Strict eligibility requirements must be met:

• Child-Pugh A liver function only – Child-Pugh B or C is a contraindication 1, 2
• ECOG performance status 0-1 1
• Prior sorafenib tolerance – Must have tolerated sorafenib ≥400 mg daily for at least 20 of the last 28 days before progression 3, 2
• Documented progression on sorafenib 3, 2

Critical pitfall: Patients who permanently discontinued sorafenib due to toxicity or intolerance were excluded from the pivotal RESORCE trial and should not routinely receive regorafenib, as both drugs share nearly identical molecular structures and overlapping toxicity profiles 4, 2. The REFINE study suggests some patients who did not tolerate sorafenib may tolerate regorafenib, but this remains preliminary 5.

Dosing Regimen

Standard dose: 160 mg orally once daily on days 1-21 of each 28-day cycle 6, 2

Continue treatment until:

• Disease progression (clinical or radiological)
• Unacceptable toxicity
• Patient no longer deriving clinical benefit 2

Dose Modification Strategy for Toxicities

Grade 3-4 adverse events require systematic dose reduction:

First dose reduction:

• 120 mg daily (3 weeks on/1 week off)

Second dose reduction:

• 80 mg daily (3 weeks on/1 week off)

Third occurrence of Grade 3 or persistent toxicity:

• Permanently discontinue 2

Management of specific toxicities:

• Hand-foot skin reaction (Grade 3,13% incidence): Interrupt treatment until Grade ≤1, then resume at reduced dose 3, 2
• Hypertension (Grade 3-4,15% incidence): Interrupt until blood pressure controlled (<140/90 mmHg), then resume at reduced dose 3, 2
• Fatigue (Grade 3,9% incidence): Interrupt until Grade ≤2, then resume at reduced dose 3
• Diarrhea (Grade 3% incidence): Manage with anti-diarrheals; interrupt if Grade 3-4, resume at reduced dose 3

If no recovery after 30-day interruption, discontinue treatment unless the patient is deriving clear clinical benefit 2.

Required Monitoring

Baseline assessment:

• Complete blood count with differential
• Comprehensive metabolic panel (liver function tests, electrolytes, renal function)
• Coagulation studies (PT/INR)
• Blood pressure
• Thyroid function tests
• Urinalysis for proteinuria
• Pregnancy test (women of childbearing potential)

During treatment:

• Weeks 1-2: Monitor blood pressure weekly
• Weeks 3-8: Monitor blood pressure every 2 weeks
• After week 8: Monitor blood pressure at each clinic visit
• Every 2 weeks for first cycle, then before each cycle: Complete blood count, liver function tests, electrolytes
• Monthly: Thyroid function tests
• As clinically indicated: ECG if QT prolongation suspected; hand-foot examination 2

Tumor response assessment:

• CT or MRI every 8 weeks using mRECIST or RECIST 1.1 criteria 2

Expected Outcomes

Based on the RESORCE trial 3, 2, 7:

• Median overall survival: 10.6 months (vs 7.8 months placebo; HR 0.63, P<0.0001)
• Median progression-free survival: 3.1 months by mRECIST (vs 1.5 months placebo; HR 0.46, P<0.0001)
• Objective response rate: 11% by mRECIST (vs 4% placebo)
• Disease control rate: 65% (vs 36% placebo)

Special Populations

Post-liver transplant HCC recurrence: Regorafenib can be used cautiously in liver transplant recipients with HCC recurrence who tolerated sorafenib, though dose reductions are frequently required (61% in one series). Monitor immunosuppressant levels closely as drug-drug interactions may increase levels 8. No liver rejection was observed in a 28-patient multicenter study, but all patients experienced at least one adverse event 8.

After first-line atezolizumab-bevacizumab failure: Regorafenib can be considered, though prospective data are lacking 1. This represents expert consensus extrapolation from sorafenib-progression data 1.

After first-line lenvatinib failure: Regorafenib is a reasonable option based on guideline consensus, though not specifically studied 1.

Contraindications

Absolute:

• Child-Pugh B or C liver function 1, 2
• ECOG performance status ≥2
• Inability to tolerate sorafenib ≥400 mg daily for ≥20 days 2
• Pregnancy or breastfeeding 2

Relative:

• Recent gastrointestinal perforation or fistula
• Uncontrolled hypertension
• Active bleeding
• Recent arterial thrombotic events 2